Raymond James Upgrades Tvardi Therapeutics to Outperform, Sets $10 Target on Strong TTI-109 Data
Tvardi’s new drug TTI-109 showed strong early results, fewer side effects, and potential in autoimmune diseases, boosting investor confidence.
NOTRELOAD AI
Apple Commits Over $30 Billion to U.S. Manufacturing in Major Broadcom Deal
The largest investment under Apple’s American Manufacturing Program.
Wall Street Boosts Compass Pathways as COMP360 Durability Data Strengthens Path to 2027 Approval
Positive six-month COMP360 results trigger analyst upgrades and higher price targets for Compass Pathways. Strong durability data clears path to potential 2027 FDA approval in treatment-resistant depression.
William Blair Initiates Outperform Coverage on Zura Bio, Citing Strong Potential for Tibulizumab
William Blair cites strong upside potential for lead candidate tibulizumab in hidradenitis suppurativa and systemic sclerosis.
Chemomab Merges with Scipher Medicine to Advance AI-Powered Precision Treatment for Rheumatoid Arthritis
Chemomab and Scipher Medicine announce merger to develop nebokitug, a first-in-class anti-CCL24 antibody, in an AI-driven Phase 2 trial for rheumatoid arthritis. $30M new funding secured.
Dream Finders Homes Raises All-Cash Bid for Beazer Homes to $32 Per Share
Beazer’s board previously rejected lower bids.